Comparative efficacy of GLP‐1 RA, tirzepatide and SGLT‐2 inhibitors in metabolic liver disease: A network meta‐analysis
This NMA demonstrated that GLP-1 RAs, SGLT-2 inhibitors and tirzepatide significantly improve surrogate markers of NAFLD, with exenatide and tirzepatide showing the greatest efficacy in reducing hepatic steatosis. PROSPERO ID CRD42024609736.
Authors
- Yusuf Ziya Şener (ORCID: https://orcid.org/0000-0001-5151-5133)
- Andrea Katrin Faour (ORCID: https://orcid.org/0009-0006-9039-0197)
- Elvira Meni Maria Gkrinia (ORCID: https://orcid.org/0009-0002-1255-8653)
- Smaro Palaska
- Anastasios Poutachidis
- Rehena Sultana
- Seher Sener
- Andrej Belančić
Institutions
- University of Rijeka (HR)
- Aristotle University of Thessaloniki (GR)
- Duke-NUS Medical School (SG)
Publication Details
- Journal
- British Journal of Clinical Pharmacology
- Published
- 2026-02-17
- DOI
- https://doi.org/10.1002/bcp.70492
- Primary Topic
- Liver Disease Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00